27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Catalent, Inc. (NYSE:CTLT)’s plans for expansion of its biologics segment are likely to bring the stock back after weak second-quarter comps and reaccelerate growth through 2019, according to Raymond James.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Michael Baker of Raymond James upgraded Catalent from Market Perform to Outperform and assigned the stock a $48 price target.
The Thesis
Catalent is an American biotech company and leading drug development, delivery and supply partner.
While Catalent reported disappointing comp figures in Q2, this negative catalyst has been largely priced into the stock, Baker said in a Wednesday note.
Catalent’s acquisitions of Cook and Accucaps, along with the “aggressive” expansion of its Madison, Wisconsin biologics facility, have strengthened the company’s competitive standing in the biologics space and increased its revenue exposure, the analyst said.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
“We are confident that CTLT will enter fiscal 2019 with rising momentum and an attractive setup that includes strong biologics top-line growth and continued delevering and diversification of the business.”
The biologics segment is a strategic concentration of Catalent's focus on specialty medicines for targeted patient populations, Baker said.
“This is achieved by focusing investment on smaller batch size capability, typically under 5,000 liters, which also allows for the increased flexibility that is a priority for these type of clients, who typically lack the desire to build internal infrastructure”
Price Action
At the time of publication, Catalent shares were trading up 2.7 percent at $41.61.
Related Links:
Benzinga's Top Upgrades, Downgrades For March 21, 2018
7 Biotech Stocks With Clinical Trial Outcomes In March
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.